BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24307543)

  • 1. Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
    Nadin SB; Sottile ML; Montt-Guevara MM; Gauna GV; Daguerre P; Leuzzi M; Gago FE; Ibarra J; Cuello-Carrión FD; Ciocca DR; Vargas-Roig LM
    Cell Stress Chaperones; 2014 Jul; 19(4):493-505. PubMed ID: 24307543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy.
    Vargas-Roig LM; Gago FE; Tello O; Aznar JC; Ciocca DR
    Int J Cancer; 1998 Oct; 79(5):468-75. PubMed ID: 9761114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.
    Vargas-Roig LM; Cuello-Carrión FD; Fernández-Escobar N; Daguerre P; Leuzzi M; Ibarra J; Gago FE; Nadin SB; Ciocca DR
    Mol Oncol; 2008 Jun; 2(1):102-11. PubMed ID: 19383332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
    Collie-Duguid ES; Sweeney K; Stewart KN; Miller ID; Smyth E; Heys SD
    Breast Cancer Res Treat; 2012 Apr; 132(3):807-18. PubMed ID: 21695460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
    West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH
    Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
    Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
    Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
    Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
    Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
    Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
    Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
    Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
    Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
    J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
    Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
    JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular markers of DNA damage and repair in cervical cancer patients treated with cisplatin neoadjuvant chemotherapy: an exploratory study.
    Real NE; Castro GN; Darío Cuello-Carrión F; Perinetti C; Röhrich H; Cayado-Gutiérrez N; Guerrero-Gimenez ME; Ciocca DR
    Cell Stress Chaperones; 2017 Nov; 22(6):811-822. PubMed ID: 28608263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp27, Hsp70 and mismatch repair proteins hMLH1 and hMSH2 expression in peripheral blood lymphocytes from healthy subjects and cancer patients.
    Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
    Cancer Lett; 2007 Jul; 252(1):131-46. PubMed ID: 17276589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
    Ciocca DR; Green S; Elledge RM; Clark GM; Pugh R; Ravdin P; Lew D; Martino S; Osborne CK
    Clin Cancer Res; 1998 May; 4(5):1263-6. PubMed ID: 9607585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
    Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
    Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
    Zhang J; Jiang H; Zhang J; Bao G; Zhang G; Wang H; Wang X
    BMC Cancer; 2021 Dec; 21(1):1301. PubMed ID: 34872507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.